Eli Lilly and Company (LLY) Diabetes Medication Successful in Children and Adolescents

Eli Lilly and Co. (NYSE:LLY) is one of the best beginner stocks to buy, according to analysts. On September 17, the company announced that its diabetes medication, Mounjaro, delivered positive results in Phase 3 Trials in children and adolescents with type 2 diabetes.

The diabetes medication reportedly demonstrated significant improvements in blood sugar control and body mass index. The Phase 3 SURPASS-PEDS trial met its primary endpoints on reducing A1C levels by an average of 2.2% after 30 weeks of treatment. The trials also achieved secondary endpoints whereby 86.1% of participants on a 10mg dose reached a target A1C of 6.5% or lower.

“Youth living with type 2 diabetes often face a more aggressive disease course,” said Tamara Hannon, lead trial investigator and director of the Clinical Diabetes Program at Indiana University School of Medicine.

Following the successful trials, Eli Lilly has submitted results to the global regulatory agencies seeking an expanded indication for Mounjaro.

Eli Lilly and Company (NYSE:LLY) is a global pharmaceutical corporation focused on discovering, developing, manufacturing, and marketing medicines to treat a range of medical conditions, with a primary focus on diabetes, oncology, immunology, neuroscience, and obesity.

While we acknowledge the potential of LLY as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 10 Best Tech Stocks to Buy According to Cathie Wood and 13 Best Tech Stocks to Buy for the Long Term.

Disclosure: None. This article is originally published at Insider Monkey.